anti-PD-L1 monoclonal antibody BGB-A333

{
  "id": "MLC-T-ONC-011002",
  "term": "anti-PD-L1 monoclonal antibody BGB-A333",
  "field": "Oncology and biomedicine",
  "definition": "A humanized immunoglobulin G1 (IgG1)-variant monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-L1 monoclonal antibody BGB-A333 specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-L1/PD-1 signaling, increases T-cell expansion and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. In addition, BGB-A333 blocks the interaction between PD-L1 and its other receptor, the immunostimulatory molecule cluster of differentiation 80 (CD80; B7-1). This prevents PD-L1/CD80 signaling and inhibits the induction of PD-L1-induced apoptosis of activated CD8+ T cells and increases T-cell proliferation. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on activated T cells suppresses the immune system and results in immune evasion. PD-1 negatively regulates T-cell activation.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-pd-l1-monoclonal-antibody-bgb-a333/"
}